Literature DB >> 31259427

Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Ibrahim Aldoss1, Dongyun Yang2, Raju Pillai3, James F Sanchez1, Matthew Mei1, Ahmed Aribi1, Haris Ali1, Karamjeet Sandhu1, Monzr M Al Malki1, Amandeep Salhotra1, Samer Khaled1, Weili Sun4, Margaret O'Donnell1, David Snyder1, Ryotaro Nakamura1, Anthony S Stein1, Stephen J Forman3, Guido Marcucci1, Vinod Pullarkat1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31259427      PMCID： PMC8855495          DOI： 10.1002/ajh.25567

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

2.  Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.

Authors:  Ibrahim Aldoss; Dongyun Yang; Ahmed Aribi; Haris Ali; Karamjeet Sandhu; Monzr M Al Malki; Matthew Mei; Amandeep Salhotra; Samer Khaled; Ryotaro Nakamura; David Snyder; Margaret O'Donnell; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Haematologica       Date:  2018-03-15       Impact factor: 9.941

Review 3.  Genomics of Acute Myeloid Leukemia Diagnosis and Pathways.

Authors:  Lars Bullinger; Konstanze Döhner; Hartmut Döhner
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

4.  Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Authors:  F Traina; V Visconte; P Elson; A Tabarroki; A M Jankowska; E Hasrouni; Y Sugimoto; H Szpurka; H Makishima; C L O'Keefe; M A Sekeres; A S Advani; M Kalaycio; E A Copelan; Y Saunthararajah; S T Olalla Saad; J P Maciejewski; R V Tiu
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

5.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

6.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113
  6 in total
  16 in total

1.  Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.

Authors:  Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Robert T Williams; Martin S Tallman; Amer M Zeidan; Maximilian Stahl
Journal:  Haematologica       Date:  2020-01-23       Impact factor: 9.941

2.  Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Authors:  Maximilian Stahl; Kamal Menghrajani; Andriy Derkach; Alexander Chan; Wenbin Xiao; Jacob Glass; Amber C King; Anthony F Daniyan; Christopher Famulare; Bernadette M Cuello; Troy Z Horvat; Omar Abdel-Wahab; Ross L Levine; Aaron D Viny; Eytan M Stein; Sheng F Cai; Mikhail Roshal; Martin S Tallman; Aaron D Goldberg
Journal:  Blood Adv       Date:  2021-03-09

3.  Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.

Authors:  Ibrahim Aldoss; Sanjeet Dadwal; Jianying Zhang; Bernard Tegtmeier; Matthew Mei; Shukaib Arslan; Monzr M Al Malki; Amandeep Salhotra; Haris Ali; Ahmed Aribi; Karamjeet Sandhu; Samer Khaled; David Snyder; Ryotaro Nakamura; Anthony S Stein; Stephen J Forman; Guido Marcucci; Vinod Pullarkat
Journal:  Blood Adv       Date:  2019-12-10

4.  Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients.

Authors:  Sylvain Garciaz; Marie-Anne Hospital; Anne-Sophie Alary; Colombe Saillard; Yosr Hicheri; Bilal Mohty; Jérôme Rey; Evelyne D'Incan; Aude Charbonnier; Ferdinand Villetard; Valerio Maisano; Laura Lombardi; Antoine Ittel; Marie-Joelle Mozziconacci; Véronique Gelsi-Boyer; Norbert Vey
Journal:  Cancers (Basel)       Date:  2022-04-16       Impact factor: 6.575

Review 5.  Targeting Bcl-2 Proteins in Acute Myeloid Leukemia.

Authors:  Yunxiong Wei; Yaqing Cao; Rui Sun; Lin Cheng; Xia Xiong; Xin Jin; Xiaoyuan He; Wenyi Lu; Mingfeng Zhao
Journal:  Front Oncol       Date:  2020-11-05       Impact factor: 6.244

Review 6.  Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.

Authors:  Naseema Gangat; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2020-11-23       Impact factor: 11.037

7.  Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation.

Authors:  Maansi Joshi; Joselle Cook; Kristen McCullough; Ahmad Nanaa; Naseema Gangat; James M Foran; Hemant S Murthy; Mohamed A Kharfan-Dabaja; Lisa Sproat; Jeanne Palmer; Animesh Pardanani; Ayalew Tefferi; Kebede Begna; Michelle Elliot; Aref Al-Kali; Mrinal Patnaik; Mithun V Shah; William J Hogan; Mark R Litzow; Hassan B Alkhateeb
Journal:  Blood Cancer J       Date:  2021-03-04       Impact factor: 11.037

8.  [Efficacy and safety of venetoclax and azacitidine in the treatment of refractory and relapsed acute myeloid leukemia].

Authors:  L H Zong; X X Wu; J Zhang; M Y Li; B Q Song; J Y Kong; X Kong; X H Hu; X B Bao; H Y Qiu; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-10-14

Review 9.  Treatment for Relapsed/Refractory Acute Myeloid Leukemia.

Authors:  Felicitas Thol; Michael Heuser
Journal:  Hemasphere       Date:  2021-06-01

10.  Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting.

Authors:  Juan Tong; Na Zhao; Xing Hu; Wen Yao; Yaxin Cheng; Li Zhou; Huilan Liu; Liangquan Geng; Zimin Sun; Changcheng Zheng
Journal:  Cancer Manag Res       Date:  2021-07-12       Impact factor: 3.989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.